View Older Stories View More Recent Stories

May 2, 2022 10:00AM Scribe Therapeutics Expands Collaboration With Biogen to Second Target
Apr 29, 2022 06:30PM SINOVAC Reports Unaudited Second Half of 2021 Financial Results and Files 2021 Annual Report on Form 20-F
Apr 8, 2022 05:21PM Form SC 13D/A Arcutis Biotherapeutics, Filed by: ORBIMED ADVISORS LLC
Apr 1, 2022 05:07PM Form SC 13D/A PMV Pharmaceuticals, Filed by: ORBIMED ADVISORS LLC
Apr 1, 2022 10:00AM Scribe Therapeutics to Participate in Upcoming Goldman Sachs The New Guard: Privates Leading the Disruption in Healthcare Investor Conference
Mar 17, 2022 07:30AM Gennao Bio Strengthens Board of Directors with Appointments of Peter Thompson, M.D., and Bradley Campbell
Mar 15, 2022 04:31PM Form SC 13D/A Sierra Oncology, Inc. Filed by: ORBIMED ADVISORS LLC
Mar 9, 2022 10:00AM Scribe Therapeutics Appoints David Parrot as Chief Financial Officer and George Manning as Controller
Mar 7, 2022 07:00AM Brookline Capital Markets Announces Promotions
Feb 15, 2022 09:43PM Form 4 Kinnate Biopharma Inc. For: Feb 11 Filed by: ORBIMED ADVISORS LLC
Feb 14, 2022 04:42PM Form 13F-HR ORBIMED ADVISORS LLC For: Dec 31
Feb 11, 2022 05:38PM Form SC 13G/A Xenon Pharmaceuticals Filed by: ORBIMED ADVISORS LLC
Feb 11, 2022 05:19PM Form SC 13G/A X4 Pharmaceuticals, Inc Filed by: ORBIMED ADVISORS LLC
Feb 11, 2022 05:17PM Form SC 13G/A Verrica Pharmaceuticals Filed by: ORBIMED ADVISORS LLC
Feb 11, 2022 05:15PM Form SC 13G VectivBio Holding AG Filed by: ORBIMED ADVISORS LLC
Feb 11, 2022 05:10PM Form SC 13G/A VistaGen Therapeutics, Filed by: ORBIMED ADVISORS LLC
Feb 11, 2022 05:07PM Form SC 13G/A Harpoon Therapeutics, Filed by: ORBIMED ADVISORS LLC
Feb 11, 2022 05:04PM Form SC 13G/A Strongbridge Biopharma Filed by: ORBIMED ADVISORS LLC
Feb 11, 2022 05:03PM Form SC 13G/A Pandion Therapeutics, Filed by: ORBIMED ADVISORS LLC
Feb 11, 2022 05:03PM Form SC 13G Sonendo, Inc. Filed by: ORBIMED ADVISORS LLC
Feb 11, 2022 05:01PM Form SC 13G/A NeuroPace Inc Filed by: ORBIMED ADVISORS LLC
Feb 11, 2022 04:59PM Form SC 13G/A Theravance Biopharma, Filed by: ORBIMED ADVISORS LLC
Feb 11, 2022 04:55PM Form SC 13G/A OTONOMY, INC. Filed by: ORBIMED ADVISORS LLC
Feb 11, 2022 04:55PM Form SC 13G Protara Therapeutics, Filed by: ORBIMED ADVISORS LLC
Feb 11, 2022 04:51PM Form SC 13G RxSight, Inc. Filed by: ORBIMED ADVISORS LLC
Feb 11, 2022 04:48PM Form SC 13G/A Mereo Biopharma Group Filed by: ORBIMED ADVISORS LLC
Feb 11, 2022 04:48PM Form SC 13G/A MeiraGTx Holdings plc Filed by: ORBIMED ADVISORS LLC
Feb 11, 2022 04:47PM Form SC 13G/A Crinetics Pharmaceutical Filed by: ORBIMED ADVISORS LLC
Feb 11, 2022 04:47PM Form SC 13G Jounce Therapeutics, Filed by: ORBIMED ADVISORS LLC
Feb 11, 2022 04:41PM Form SC 13G/A Larimar Therapeutics, Filed by: ORBIMED ADVISORS LLC
Feb 11, 2022 04:40PM Form SC 13G Gracell Biotechnologies Filed by: ORBIMED ADVISORS LLC
Feb 11, 2022 04:40PM Form SC 13G/A FLUIDIGM CORP Filed by: ORBIMED ADVISORS LLC
Feb 11, 2022 04:40PM Form SC 13G/A Forte Biosciences, Inc. Filed by: ORBIMED ADVISORS LLC
Feb 11, 2022 04:32PM Form SC 13G CATALYST BIOSCIENCES, Filed by: ORBIMED ADVISORS LLC
Feb 11, 2022 04:22PM Form SC 13G/A Applied Therapeutics Filed by: ORBIMED ADVISORS LLC
Feb 11, 2022 04:21PM Form SC 13G/A Aeglea BioTherapeutics, Filed by: ORBIMED ADVISORS LLC
Feb 11, 2022 04:16PM Form SC 13G/A Adverum Biotechnologies, Filed by: ORBIMED ADVISORS LLC
Feb 8, 2022 08:00AM Congruence Therapeutics Inc. Announces US$50 million Series A Financing to Advance Platform Targeting Diseases of Protein Misfolding
Feb 2, 2022 04:34PM Form SC 13D/A Sierra Oncology, Inc. Filed by: ORBIMED ADVISORS LLC
Jan 28, 2022 09:23PM Form 4 Sierra Oncology, Inc. For: Jan 26 Filed by: ORBIMED ADVISORS LLC
Jan 27, 2022 05:24PM Form 4 89bio, Inc. For: Jan 25 Filed by: OrbiMed Advisors Israel II Ltd
Jan 24, 2022 04:44PM Form 4 Passage BIO, Inc. For: Jan 20 Filed by: ORBIMED ADVISORS LLC
Jan 20, 2022 06:04PM Form 4 Passage BIO, Inc. For: Jan 14 Filed by: ORBIMED ADVISORS LLC
Jan 13, 2022 07:38PM Form 4 Passage BIO, Inc. For: Jan 11 Filed by: ORBIMED ADVISORS LLC
Jan 6, 2022 07:00AM Odyssey Therapeutics Acquires Rahko, a Quantum Machine Learning Company
Dec 30, 2021 09:00PM Form 4 Janux Therapeutics, Inc. For: Dec 29 Filed by: ORBIMED ADVISORS LLC
Dec 30, 2021 04:05PM SINOVAC Reports Unaudited First Half of 2021 Financial Results
Dec 17, 2021 05:09PM Form SC 13D/A Janux Therapeutics, Inc. Filed by: ORBIMED ADVISORS LLC
Dec 14, 2021 05:30PM Form SC 13D/A Adicet Bio, Inc. Filed by: ORBIMED ADVISORS LLC
Dec 9, 2021 02:26PM Antigua Court of Appeal Rules in Favor of SINOVAC, Upholds 2018 Judgment
View More Recent Stories View Older Stories